116 results on '"Sirachainan, E."'
Search Results
2. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer
3. Gemcitabine, carboplatin, and Epstein–Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial
4. 652O Randomized phase III VANCE study: Gemcitabine and carboplatin (GC) followed by Epstein Barr virus-specific autologous cytotoxic T lymphocytes (EBV-CTL) versus the same chemotherapy as first-line treatment for advanced nasopharyngeal carcinoma (NPC)
5. Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen
6. Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen
7. CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients
8. 511P Real-world survival outcomes of Asian metastatic colorectal cancer patients undergoing hepatectomy from the AsianmCRCRegistry
9. ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen
10. A phase I study of the CDK4/6 inhibitor, palbociclib in combination with cetuximab and intensity modulated radiation therapy (IMRT) for locally advanced squamous cell carcinoma of the head and neck (SCCHN); A result of dose escalation cohort
11. Long term outcomes of preoperative concurrent CapeOx/RT in locally advanced rectal cancer
12. Rapid Flare of Brain Metastases in ALK-Positive Non-Small Cell Lung Cancer after Stopping Crizotinib
13. P3.15-24 Ramathibodi Lung Cancer Consortium (RLC) Model: Multidisciplinary Team Approach Improves Lung Cancer Patients’ Survival Outcome
14. P3.09-19 Matched Thai Lung Cancer Patients Tissue and cfDNA Molecular Profile by NGS
15. A phase I/II dose escalation study of the CDK4/6 inhibitor, palbociclib in combination with cetuximab and intensity modulated radiation therapy (IMRT) for locally advanced squamous cell carcinoma of the head and neck (SCCHN)
16. P3.03-020 Unique Molecular Profile of NSCLC in Thai Population
17. Molecular alterations and clinical prognostic factors for cholangiocarcinoma in Thai population
18. Molecular alterations and clinical prognostic factors for cholangiocarcinoma in Thai population
19. 527P An observational study of quality of life in Thai colorectal cancer patients who received chemotherapy
20. 1123P - A phase I study of the CDK4/6 inhibitor, palbociclib in combination with cetuximab and intensity modulated radiation therapy (IMRT) for locally advanced squamous cell carcinoma of the head and neck (SCCHN); A result of dose escalation cohort
21. 95P - Long term outcomes of preoperative concurrent CapeOx/RT in locally advanced rectal cancer
22. An optimal cumulative dose of cisplatin in chemoradiotherapy as a definitive treatment for non-metastatic nasopharyngeal carcinoma: a retrospective multicenter study
23. 1118TiP - A phase I/II dose escalation study of the CDK4/6 inhibitor, palbociclib in combination with cetuximab and intensity modulated radiation therapy (IMRT) for locally advanced squamous cell carcinoma of the head and neck (SCCHN)
24. 2383 Clinical prognostic factors and genomic alterations of cholangiocarcinoma in Thai population
25. P0131 Factors affecting significant weight loss after concurrent chemoradiotherapy followed by adjuvant chemotherapy for locally advanced nasopharyngeal carcinoma
26. P0080 Incidence and associated factors of cisplatin-induced chronic kidney disease after chemoradiotherapy for nasopharyngeal carcinoma
27. P0029 A pilot study of molecular alterations and the clinical prognostic factors of cholangiocarcinoma in the Thai population
28. 426. Incidence of free colorectal cancer cells in peritoneal cavity and correlation with clinicopathologic variables: An analysis of 275 patients undergoing curative intent resection for colorectal cancer
29. Molecular alterations and clinical prognostic factors for cholangiocarcinoma in Thai population.
30. 998P - An optimal cumulative dose of cisplatin in chemoradiotherapy as a definitive treatment for non-metastatic nasopharyngeal carcinoma: a retrospective multicenter study
31. AOSOP4 PREOPERATIVE CONCURRENT CAPOX RADIOTHERAPY IN THAI PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER
32. AOS23 O6-methylguanine-DNA-methyltransferase expression in Thai patients with malignant gliomas: Outcome and response to treatment in Ramathibodi Hospital
33. AOS17 KRAS genotypes in Thai patients with colorectal cancer
34. Cytochrome P450 2D6 polymorphisms of Thai patients with breast cancer and their outcomes of adjuvant tamoxifen.
35. P22 Olfactory neuroblastoma – Ramathibodi Hospital experience
36. Dihydropyrimidine dehydrogenase (DPD) single nucleotide polymorphisms (SNP) in Thai patients treated with 5-FU based regimens
37. Peripheral blood quantitative PCR analysis of EBV DNA in nasopharyngeal carcinoma
38. 124P Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer.
39. A new era of the Asian clinical research network: a report from the ATLAS international symposium.
40. Healthcare coverage affects survival of EGFR-mutant Thai lung cancer patients.
41. Treatment outcomes of advanced hepatocellular carcinoma in real-life practice: Chemotherapy versus multikinase inhibitors.
42. Clinical correlations with EGFR circulating tumor DNA testing in all-stage lung adenocarcinoma.
43. Clinical Study of Long-Term Survival in Colorectal Cancer Patients in Thailand: A 10-Year Follow-Up.
44. Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study.
45. Effects of polymorphisms in the MTHFR gene on 5-FU hematological toxicity and efficacy in Thai colorectal cancer patients.
46. Effect of Primary Tumor Location on Second- or Later-Line Treatment With Anti-Epidermal Growth Factor Receptor Antibodies in Patients With Metastatic Colorectal Cancer: A Retrospective Multi-Center Study.
47. Capturing tumour heterogeneity in pre- and post-chemotherapy colorectal cancer ascites-derived cells using single-cell RNA-sequencing.
48. Optimizing outcomes for patients with metastatic prostate cancer: insights from South East Asia Expert Panel.
49. Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy.
50. Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.